Piper Sandler analyst Christopher Raymond maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and maintains the target price at $1,195.
According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's third-quarter results surpassed expectations marginally in terms of revenue and more significantly regarding earnings per share. However, the performance of the Eylea franchise was a dominant concern. The impending launch of a biosimilar version of Eylea by a competitor has raised questions about the future of the franchise. This includes the pace at which the standard dose market may decline, which may be faster than current market estimates, and the potential negative impact on the high dose variant.
The recent decline in Regeneron's share value is viewed as an overextension. This sentiment is in response to reactions concerning the Pavblu news, the less-than-anticipated Q4 Eylea HD outlook, and the absence of forward-looking growth projections for Eylea.
The stock's decline post-Q3 earnings was somewhat unexpected. This was given the understanding that near- and long-term consensus estimates for the ophthalmology franchise might have been overly optimistic. Nonetheless, it appears that the fundamental fair value of Regeneron is currently well above where the shares are trading.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
